Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma

Allergol Int. 2024 Jul;73(3):473-476. doi: 10.1016/j.alit.2024.03.005. Epub 2024 Apr 6.

Affiliations

¹ Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
² Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. Electronic address: [email protected].
³ Department of Genome Biology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

PMID: 38582716
DOI: 10.1016/j.alit.2024.03.005

No abstract available

Publication types

Letter

MeSH terms

Adult
Anti-Asthmatic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized* / therapeutic use
Asthma* / blood
Asthma* / drug therapy
Eosinophilia / blood
Eosinophilia / drug therapy
Eosinophils* / immunology
Female
Humans
Leukocyte Count
Male
Middle Aged
Phenotype*
Severity of Illness Index
Treatment Outcome

Substances

mepolizumab
Antibodies, Monoclonal, Humanized
Anti-Asthmatic Agents